ArticleMolecular biotechnology2026
Exosomal LncRNA MALAT1 Derived from Hepatocytes in Nonalcoholic Fatty Liver Disease Regulates the miR-579-3p/Keap1/Nrf2 Pathway to Exacerbate Obstructive Sleep Apnea Syndrome.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectiveObstructive sleep apnea syndrome (OSAS) is a common sleep breathing disorder, and nonalcoholic fatty liver disease (NAFLD) may affect OSAS. This study aimed to explore the influence of exosomes (Exos) derived from liver cells in NAFLD on the progression of OSAS and the underlying molecular mechanisms.
methodsC57BL/6J mice were exposed to chronic intermittent hypoxia (CIH) to establish an OSAS animal model, and SH-SY5Y cells treated with CIH were used as the in vitro cellular model. THLE-2 cells treated with oleic acid (OA) were used to simulate NAFLD, and Exos were isolated from these cells. The morphological characteristics of Exos were observed by transmission electron microscopy (TEM), and their particle size distribution and concentration were determined by nanoparticle tracking analysis (NTA). Furthermore, potential binding sites between lncRNA MALAT1 and miR-579-3p, as well as between miR-579-3p and Keap1 mRNA, were predicted using the starBase database. HE staining was used to assess histopathological damage in mouse hippocampal tissues, and TUNEL staining was performed to assess neuronal apoptosis.
resultsExos derived from OA-treated THLE-2 cells significantly upregulated the expression of oxidative stress markers (ROS and MDA) and proinflammatory cytokines (IL-1β, IL-6, and TNF-α) while downregulating the activity of antioxidant factors, including SOD and GSH. These alterations exacerbated neuronal damage in both the hippocampal tissues of OSAS mice and CIH-induced SH-SY5Y cells. Mechanistically, the lncRNA MALAT1 was markedly upregulated in Exos, which promoted Keap1 expression and suppressed Nrf2 expression through MALAT1 delivery, thereby activating the Keap1/Nrf2 signaling pathway. Furthermore, MALAT1 was observed to bind and downregulate miR-579-3p expression, consequently relieving its inhibitory effect on Keap1 and ultimately aggravating neuronal injury in OSAS mice.
conclusionExosomal lncRNA MALAT1 derived from NAFLD hepatocytes exacerbates OSAS-associated neuronal injury by suppressing miR-579-3p expression and subsequently activating the Keap1/Nrf2 signaling pathway. This discovery not only reveals the molecular link between NAFLD and OSAS-induced neurological damage but also provides critical insights into the pathogenesis of OSAS and potential therapeutic strategies.
Indexed as
Identifiers
40906321What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.